Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Kei Sakamoto et al. published in JACC Asia:
“In this real-world postmarketing surveillance study evaluated the use of andexanet alfa, a specific reversal agent for factor Xa inhibitors (FXaIs), in patients presenting with life-threatening or uncontrolled bleeding.
A total of 365 Japanese patients were included, with a median age of 80 years, representing a high-risk, elderly population frequently encountered in clinical practice.
Bleeding profile
The majority of cases involved intracranial hemorrhage (71.5%), followed by gastrointestinal bleeding, highlighting the severity of presentations treated with andexanet alfa.
Effectiveness
- 80.9% of patients achieved ‘effective’ or ‘excellent’ hemostasis
- 30-day survival rate: 83.5% (95% CI: 77.4%–88.0%)
These findings demonstrate robust hemostatic efficacy in a critically ill population
Safety profile
- Adverse drug reactions: 17.5%
- Thrombotic events: 8.8% (notably cerebral infarction)
- Rebleeding events: 1.4%
Notably, more than half of adverse events occurred within the first 72 hours, emphasizing the need for close early monitoring.
Clinical interpretation
Andexanet alfa provides rapid reversal of anticoagulation, enabling effective bleeding control.
However, the associated prothrombotic risk requires careful patient selection and thoughtful timing of anticoagulation resumption.
Conclusion
Andexanet alfa is a clinically effective and essential therapeutic option for FXaI-associated major bleeding, with an acceptable safety profile when used under strict monitoring in high-risk patients.”
Title: Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan
Authors: Kei Sakamoto, Miyo Ishihara, Hiroko Kato, Hyosung Kim, Masaki Okuda, Shunsuke Hiroki, Masatoshi Koga, Kazunori Toyoda
Read the Full Article on JACC Asia
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery